Kiran Mazumdar-Shaw - Sep 12, 2024 Form 3 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
Director, 10%+ Owner
Signature
/s/ Lara Meisner, Attorney-in-Fact
Stock symbol
BCAX
Transactions as of
Sep 12, 2024
Transactions value $
$0
Form type
3
Date filed
9/12/2024, 09:11 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BCAX Common Stock 16.7K Sep 12, 2024 Direct
holding BCAX Common Stock 116K Sep 12, 2024 By Biocon Limited F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BCAX Series Seed Redeemable Convertible Preferred Stock Sep 12, 2024 Common Stock 4.33M By Biocon Limited F1, F2
holding BCAX Series Seed Redeemable Convertible Preferred Stock Sep 12, 2024 Common Stock 1.08M By Biocon Pharma Inc. F2, F3
holding BCAX Series Seed Redeemable Convertible Preferred Stock Sep 12, 2024 Common Stock 325K By Glentech International F2, F4
holding BCAX Series Seed Redeemable Convertible Preferred Stock Sep 12, 2024 Common Stock 433K By Carica Investments F2, F5
holding BCAX Stock Option (Right to Buy) Sep 12, 2024 Common Stock 8.33K $4.10 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Biocon Limited ("Biocon Ltd"). The Reporting Person is the managing member of Biocon Ltd and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F2 Each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") is convertible into Common Stock on a 9.2435-to-one basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Preferred Stock has no expiration date.
F3 Shares held by Biocon Pharma Inc. ("Biocon Pharma"). The Reporting Person is the managing member of Biocon Pharma and disclaims and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F4 Shares held by Glentech International ("Glentech"). The Reporting Person is the managing member of Glentech and disclaims beneficial ownership of such shares for purposes of Section 16 of Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F5 Shares held by Carica Investments ("Carica"). The Reporting Person is the managing partner of Carica and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F6 The shares underlying this option vest in sixteen equal quarterly installments following September 22, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney